Drug Watch

The Cutaneous Connection: Episode 30- Impact of the JAK Inhibitor Approval Delays
September 02, 2021

Mark Lebwohl, MD, takes a deep dive in the recent delay in approval for multiple JAK inhibitor drugs for treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis. He also discusses the impact of the delay, as well as the benefits of JAK inhibitors for inflammatory skin diseases, and an outlook for the future of this drug class.

FDA Requiring Black Box Warning for Certain JAK Inhibitors
September 02, 2021

The FDA is now requiring black box warning for certain JAK inhibitors used to treat arthritis. This news comes amid delay in FDA approval for multiple JAK inhibitors for the treatment of inflammatory skin conditions.

Abrocitinib and Topical Therapy Safe, Effective for Atopic Dermatitis in Teens
August 23, 2021

A phase 3 trial studied the effectiveness of oral abrocitinib along with topical therapy for moderate-to-severe atopic dermatitis in teens.